The prognostic relevance of exercise pulmonary hypertension in cardiac and pulmonary diseases.
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
3
7
2024
Statut:
aheadofprint
Résumé
In this review, we provide an overview of the prognostic implications of exPH in patients with various common cardiac and pulmonary diseases. Exercise pulmonary hypertension (exPH) has been recently re-introduced in the current European Society of Cardiology/European Respiratory Society pulmonary hypertension guidelines. Accordingly, exPH is defined as a mean pulmonary arterial pressure (mPAP)/cardiac output (CO) slope greater than 3 mmHg/l/min. Key considerations for this re-introduction included increasing understanding on normal pulmonary hemodynamics during exercise and the broadly available evidence on the association of an abnormal mPAP/CO slope with poor survival in the general population and in different disease entities. Exercise (patho-)physiology has opened a new field for clinical research facilitating recognition of cardiovascular and pulmonary vascular diseases in an early stage. Such early recognition with significant prognostic and possibly therapeutic relevance, but being undetectable at rest, makes exercise pulmonary hemodynamics particularly interesting for common diseases, such as valvular heart disease, left heart disease, and chronic pulmonary disease.
Identifiants
pubmed: 38958564
doi: 10.1097/MCP.0000000000001096
pii: 00063198-990000000-00173
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61:2200879.
Zeder K, Banfi C, Steinrisser-Allex G, et al. Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. Eur Respir J 2022; 60:2103181.
Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40:3297–3317.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43:561–632.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e35–e71.
Ho JE, Zern EK, Lau ES, et al. Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort. J Am Coll Cardiol 2020; 75:17–26.
Douschan P, Avian A, Foris V, et al. Prognostic value of exercise as compared to resting pulmonary hypertension in patients with normal or mildly elevated pulmonary arterial pressure. Am J Respir Crit Care Med 2022; 206:1418–1423.
Saggar R, Khanna D, Furst DE, et al. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. Arthritis Rheum 2010; 62:3741–3750.
Hager WD, Collins I, Tate JP, et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients. Clin Respir J 2013; 7:227–236.
Nagel C, Marra AM, Benjamin N, et al. Reduced right ventricular output reserve in patients with systemic sclerosis and mildly elevated pulmonary artery pressure. Arthritis Rheumatol 2019; 71:805–816.
Kovacs G, Agusti A, Barbera JA, et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease. is there a pulmonary vascular phenotype? Am J Respir Crit Care Med 2018; 198:1000–1011.
Stamm A, Saxer S, Lichtblau M, et al. Exercise pulmonary heamodynamics predict outcome in patients with systemic sclerosis. Eur Respir J 2016; 48:1658–1667.
Zeder K, Avian A, Bachmaier G, et al. Exercise pulmonary resistances predict long-term survival in systemic sclerosis. Chest 2021; 159:781–790.
Magne J, Donal E, Mahjoub H, et al. Impact of exercise pulmonary hypertension on postoperative outcome in primary mitral regurgitation. Heart 2015; 101:391–396.
Magne J, Lancellotti P, Pierard LA. Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. Circulation 2010; 122:33–41.
Dhont S, Stassen J, Herbots L, et al. Exercise pulmonary hypertension by the mPAP/CO slope in primary mitral regurgitation. Eur Heart J Cardiovasc Imaging 2024; 25:530–538.
Magne J, Lancellotti P, O’Connor K, et al. Prediction of exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. J Am Soc Echocardiogr 2011; 24:1004–1012.
Coisne A, Aghezzaf S, Galli E, et al. Prognostic values of exercise echocardiography and cardiopulmonary exercise testing in patients with primary mitral regurgitation. Eur Heart J Cardiovasc Imaging 2022; 23:1552–1561.
Lancellotti P, Magne J, Dulgheru R, et al. Clinical significance of exercise pulmonary hypertension in secondary mitral regurgitation. Am J Cardiol 2015; 115:1454–1461.
Utsunomiya H, Hidaka T, Susawa H, et al. Exercise-stress echocardiography and effort intolerance in asymptomatic/minimally symptomatic patients with degenerative mitral regurgitation combined invasive-noninvasive hemodynamic monitoring. Circ Cardiovasc Imaging 2018; 11:e007282.
Catherine M, Nishimura RA, Bonow RO, et al. Writing Committee Members FAU-o 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021; 77:e25–e197.
Hoedemakers S, Pugliese NR, Stassen J, et al. mPAP/CO slope and oxygen uptake add prognostic value in aortic stenosis. Circulation 2024; 149:1172–1182.
Lancellotti P, Magne J, Donal E, et al. Determinants and prognostic significance of exercise pulmonary hypertension in asymptomatic severe aortic stenosis. Circulation 2012; 126:851–859.
Dobarro D, Castrodeza-Calvo J, Varela-Falcon L, et al. Exercise right heart catheterization predicts outcome in asymptomatic degenerative aortic stenosis. Rev Esp Cardiol (Engl Ed) 2020; 73:457–462.
Saito Y, Obokata M, Harada T, et al. Prognostic benefit of early diagnosis with exercise stress testing in heart failure with preserved ejection fraction. Eur J Prev Cardiol 2023; 30:902–911.
Eisman AS, Shah RV, Dhakal BP, et al. Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure. Circ Heart Fail 2018; 11:e004750.
Reddy YNV, Kaye DM, Handoko ML, et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol 2022; 7:891–899.
Saito Y, Obokata M, Harada T, et al. Disproportionate exercise-induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a noninvasive echocardiographic study. Eur J Heart Fail 2023; 25:792–802.
Caravita S, Baratto C, Filippo A, et al. Shedding light on latent pulmonary vascular disease in heart failure with preserved ejection fraction. JACC Heart Fail 2023; 11:1427–1438.
Rieth A, Richter MJ, Gall H, et al. Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. J Heart Lung Transplant 2017; 36:880–889.
Nathan SD, Barbera JA, Gaine S, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53:1801914.
Kovacs G, Avian A, Bachmaier G, et al. Severe pulmonary hypertension in COPD: impact on survival and diagnostic approach. Chest 2022; 162:202–212.
Zeder K, Avian A, Bachmaier G, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58:2100944.
Vizza CD, Hoeper MM, Huscher D, et al. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Chest 2021; 160:678–689.
Olsson KM, Hoeper MM, Pausch C, et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021; 58:2101483.
Jose A, King CS, Shlobin OA, et al. Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease. Eur Respir J 2018; 52:1801015.
Hilde JM, Skjorten I, Hansteen V, et al. Haemodynamic responses to exercise in patients with COPD. Eur Respir J 2013; 41:1031–1041.
Sassmann T, Douschan P, Foris V, et al. Abnormal pulmonary hemodynamics during exercise is associated with exercise capacity in COPD. Respir Res 2022; 23:331.
Kubo K, Ge RL, Koizumi T, et al. Pulmonary artery remodeling modifies pulmonary hypertension during exercise in severe emphysema. Respir Physiol 2000; 120:71–79.
Kovacs G, Herve P, Olschewski H. PEX-NET Clinical Research Collaboration The pulmonary haemodynamics during exercise – research network (PEX-NET) ERS Clinical Research Collaboration: investigating the prognostic relevance of exercise haemodynamics. Eur Respir J 2019; 53:1900458.